Area of research
Infectious Diseases · Emergency Medical Services
Research interest
Research focused on Ebola virus and Virology, with related work in Favipiravir, Convalescent plasma, Nucleoprotein. Notable publications include 'Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea', 'Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea', and 'Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted'.
Detection of Crimean–Congo haemorrhagic fever virus in Hyalomma marginatum ticks, southern France, May 2022 and April 2023
A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease
Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial
Rapid protection induced by a single-shot Lassa vaccine in male cynomolgus monkeys
A MOPEVAC multivalent vaccine induces sterile protection against New World arenaviruses in non-human primates
Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeys
A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains
Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques
Understanding Long-term Evolution and Predictors of Sequelae of Ebola Virus Disease Survivors in Guinea: A 48-Month Prospective, Longitudinal Cohort Study (PostEboGui)
Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study
Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot
Immune parameters and outcomes during Ebola virus disease
A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins
Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study
Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea
Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea
Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies
New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors: Table 1.
Ebola virus in West Africa: new conquered territories and new risks—or how I learned to stop worrying and (not) love Ebola virus
Nomenclature- and Database-Compatible Names for the Two Ebola Virus Variants that Emerged in Guinea and the Democratic Republic of the Congo in 2014
Exonuclease Domain of the Lassa Virus Nucleoprotein Is Critical To Avoid RIG-I Signaling and To Inhibit the Innate Immune Response